{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:30:28Z","timestamp":1787031028691,"version":"build-2736575974"},"reference-count":29,"publisher":"American Society of Consultant Pharmacists","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background<\/jats:bold>\n                    Respiratory syncytial virus (RSV) can cause severe illness, particularly in older adults, leading to thousands of hospitalizations and deaths annually among individuals aged 65 and older. In May 2023, the U.S. Food and Drug Administration (FDA) approved two vaccines,\n Arexvy\u00ae (RSVPreF3) and Abrysvo\u00ae (RSVpreF), for the prevention of RSV-related lower respiratory tract disease (LRTD) in adults aged 60 years and older. In May 2024, the FDA approved a third RSV vaccine, mRESVIA\u00ae (mRNA-1345). In June 2024, the Centers for Disease Control and Prevention\n (CDC) updated its guidance to recommend a single dose of an RSV vaccine for all adults aged 75 years and older, as well as those aged 60 to 74 years old with risk factors for severe disease. Clinical trials have demonstrated that all three vaccines are safe and effective in reducing RSV-related\n morbidity and mortality.\n                    <jats:bold>Objective<\/jats:bold>\n                    To review the literature describing the safety, efficacy, tolerability, and clinical application of RSV vaccines in older adults.\n                    <jats:bold>Data Sources<\/jats:bold>\n                    Primary literature identified through PubMed, the U.S. clinical trial registry,\n and CDC resources from 2021 to 2025, with an emphasis on randomized clinical trials and key studies supporting FDA approval.\n                    <jats:bold>Data Synthesis<\/jats:bold>\n                    Arexvy\u00ae (RSVPreF3), Abrysvo\u00ae (RSVpreF), and mRESVIA\u00ae (mRNA-1345) have demonstrated efficacy in reducing the risk of RSV-associated\n LRTD and severe RSV-associated LRTD in adults aged 60 years and older. Reported adverse effects include injection-site pain, myalgia, fatigue, and headaches. Economic analyses suggest that all three vaccines are potentially cost-effective.\n                    <jats:bold>Conclusion<\/jats:bold>\n                    RSV poses a significant\n risk of morbidity and mortality, especially in older adults. Arexvy\u00ae (RSVPreF3), Abrysvo\u00ae (RSVpreF), and mRESVIA\u00ae (mRNA-1345) have been shown to effectively prevent LRTD caused by RSV in individuals aged 60 and older. Pharmacists play a vital role in supporting CDC recommendations,\n educating patients and optimizing preventive health strategies.\n                  <\/jats:p>","DOI":"10.4140\/tcp.n.2025.402","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T04:30:27Z","timestamp":1759465827000},"page":"402-411","source":"Crossref","is-referenced-by-count":4,"title":["A Review of Respiratory Syncytial Virus Vaccines in the Older Adult"],"prefix":"10.4140","volume":"40","author":[{"given":"Brian","family":"Torres","sequence":"first","affiliation":[{"name":"James A. Haley Veterans\u2019 Hospital, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"King","sequence":"additional","affiliation":[{"name":"James A. Haley Veterans\u2019 Hospital, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Richardson","sequence":"additional","affiliation":[{"name":"James A. Haley Veterans\u2019 Hospital, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2625","reference":[{"key":"ref1","first-page":"2023","article-title":"RSV (respiratory syncytial virus). Published August 4, 2023.","volume":"24","journal-title":"Accessed September"},{"key":"ref2","article-title":"Respiratory syncytial virus (RSV).","year":"2025"},{"key":"ref3","first-page":"2025","article-title":"Preliminary estimates of RSV burden for 2024\u20132025. Published March 19, 2025.","volume":"12","journal-title":"Accessed June"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1080\/13696998.2023.2213125","article-title":"Economic burden of respiratory syncytial virus infection in adults: a systematic literature review.","volume":"26","year":"2023","journal-title":"J Med Econ."},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/infdis\/jiad189","article-title":"Estimation of the number of respiratory syncytial virus-associated hospitalizations in adults in the European Union.","volume":"228","year":"2023","journal-title":"J Infect Dis."},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-065X.2010.00972.x","article-title":"Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.","volume":"239","year":"2011","journal-title":"Immunol Rev."},{"key":"ref7","first-page":"2025","article-title":"Arexvy [package insert]. Revised May 2025","volume":"12","journal-title":"Accessed June"},{"key":"ref8","first-page":"2025","article-title":"Revised June 2025.","volume":"12","journal-title":"Accessed June"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3390\/pathogens12101259","article-title":"Respiratory syncytial virus vaccines: a review of the candidates and the approved vaccines.","volume":"12","year":"2023","journal-title":"Pathogens."},{"key":"ref10","first-page":"2025","article-title":"RSV vaccination for adults aged 60 years and older: information for healthcare providers. Published July 3, 2024","volume":"12","journal-title":"Accessed June"},{"key":"ref11","first-page":"2025","article-title":"Respiratory syncytial virus prefusion F (RSVPreF3) vaccine. In: StatPearls. Updated March 19, 2024. StatPearls Publishing; 2024.","volume":"12","journal-title":"Accessed June"},{"key":"ref12","year":"2024"},{"issue":"24","key":"ref13","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSVPreF vaccine in older adults.","volume":"389","year":"2023","journal-title":"N Engl J Med."},{"issue":"32","key":"ref14","doi-asserted-by":"crossref","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","article-title":"Use of respiratory syncytial virus vaccines in adults aged \u2265 60 years: updated recommendations of the Advisory Committee on Immunization Practices, United States, 2024.","volume":"73","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"7","key":"ref15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion F protein vaccine in older adults.","volume":"388","year":"2023","journal-title":"N Engl J Med."},{"key":"ref16","first-page":"2025","article-title":"Immunogenicity, safety, reactogenicity, and persistence of an investigational respiratory syncytial virus (RSV) vaccine in adults aged 60 years and above.","volume":"12","year":"2023","journal-title":"ClinicalTrials. gov identifier: NCT04732871."},{"key":"ref17","first-page":"2025","article-title":"A study on the immune response and safety elicited by a vaccine against respiratory syncytial virus (RSV) when given alone and together with a vaccine against influenza in adults aged 60 years and above. ClinicalTrials.gov identifier: NCT04841577. Updated October 18, 2022.","volume":"12","journal-title":"Accessed June"},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1093\/cid\/ciae010","article-title":"Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons.","volume":"78","year":"2024","journal-title":"Clin Infect Dis."},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/infdis\/jiad321","article-title":"Safety and immunogenicity of revaccination with a respiratory syncytial virus prefusion F vaccine in older adults: a phase 2b study.","volume":"229","year":"2024","journal-title":"J Infect Dis."},{"key":"ref20","article-title":"GSK shares positive data for Arexvy, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons.","year":"2025"},{"issue":"16","key":"ref21","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults.","volume":"388","year":"2023","journal-title":"N Engl J Med."},{"key":"ref22","article-title":"Pfizer announces positive top-line data for full season two efficacy of Abrysvo for RSV in older adults.","year":"2025"},{"key":"ref23","article-title":"Tools for mRESVIA (respiratory syncytial virus vaccine): resources for healthcare providers.","year":"2024"},{"issue":"10462","key":"ref24","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(24)01738-0","article-title":"Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalizations and emergency department encounters among adults aged 60 years and older in the USA, October 2023 to March 2024: a test-negative design analysis.","volume":"404","year":"2024","journal-title":"Lancet."},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1473-3099(24)00796-5","article-title":"Respiratory syncytial virus vaccine effectiveness among US veterans, September 2023 to March 2024: a target trial emulation study.","volume":"25","journal-title":"Lancet Infect Dis."},{"issue":"6","key":"ref26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/infdis\/jiac327","article-title":"Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase 1\/2 randomized clinical trial.","volume":"227","year":"2023","journal-title":"J Infect Dis."},{"issue":"11","key":"ref27","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3390\/v16111671","article-title":"Developing correlates of protection for vaccines is needed more than ever: influenza, COVID-19, and RSV infection.","volume":"16","year":"2024","journal-title":"Viruses."},{"key":"ref28","article-title":"Current CDC vaccine price list. Accessed June 12, 2025"},{"key":"ref29","first-page":"2025","article-title":"Economic analysis of RSV vaccination in older adults. Presented at: Advisory Committee on Immunization Practices (ACIP) Meeting; June 26, 2024;","volume":"12","journal-title":"Atlanta, GA. Accessed June"}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2025\/00000040\/00000010\/art00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T04:31:23Z","timestamp":1759811483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2025.402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"alternative-id":["2639-9636(20251001)40:10L.402;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2025.402","relation":{},"ISSN":["2639-9636"],"issn-type":[{"value":"2639-9636","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}